Condition

Cognitive Deficit

ClinicalTrials.gov condition label

Clinical trials5

Recruiting2

Common interventions10

Lead sponsors shown5

Clinical trials

5 shown

Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRSNCT06278532 · 2023-12-11

Isolated Versus Combined Cognitive and Motor High-tech RehabilitationNCT06820125 · 2023-07-05

Effect of Vortioxetine on Cognitive Symptoms in Patients With SchizophreniaNCT04456777 · 2020-07-01

Cognitive Remediation Therapy for Participants With Late-Life SchizophreniaNCT03695614 · 2018-10-24

Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert (NbM) in Patients With Parkinson's DiseaseNCT02763397 · 2016-05-01

Common interventions

Brief Negative Symptoms ScaleDIAGNOSTIC_TEST1 Cognitive rehabilitation: CG groupDEVICE1 Cognitive Remediation TherapyOTHER1 Combined rehabilitation: CbG groupDEVICE1 DBSDEVICE1 Motor rehabilitation: MG groupDEVICE1 NBM-DBSDEVICE1 The Calgary Depression Scale for SchizophreniaDIAGNOSTIC_TEST1 The Schizophrenia Cognition Rating ScaleDIAGNOSTIC_TEST1 VortioxetineDRUG1

Leading sponsors

Alen Greš1 Centre for Addiction and Mental Health1 Lithuanian University of Health Sciences1 Universita di Verona1 University Medical Center Groningen1

Trial status mix

RECRUITING2

UNKNOWN2

COMPLETED1

Phase mix

NA3

EARLY_PHASE11

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.